A placebo-controlled study evaluated the effects of specific immunotherapy (SIT) in a group of 29 atopic dermatitis (AD) patients associated with house dust mites (HDM), allergic asthma or rhinitis. There were 19 patients in the SIT group and 10 in the placebo group. The SCORing Atopic Dermatitis (SCORAD) index was used to assess AD severity at baseline and after 1 year. The spread, intensity and subjective signs of AD were also assessed. SCORAD scores were significantly lower in the SIT group after 1 year (P < 0.001); this was also the case for the spread (P = 0.005), intensity (P = 0.002) and subjective signs (P = 0.005) of AD. ...